Biocon Limited (BIOCON) reports a 9% rise in total income to Rs 4,391 Cr for Q1 FY27, driven by strong Biopharma growth.
Biocon Limited (BIOCON) announces the U.S. launch of Yesafili™, a biosimilar to Regeneron’s Eylea® 2 mg, expanding access to eye treatment.
Biocon Limited (NSE: BIOCON) stock moves up 5% intraday to ₹435.0, testing resistance in the healthcare & biotechnology sector.
Biocon Limited (BIOCON) publishes pivotal clinical data supporting the effectiveness of Yesafili™, a biosimilar to Eylea®.
Biocon Limited (BIOCON) partners with Duopharma Biotech to secure insulin contracts in Malaysia, valued at over MYR 225 million.
Biocon Limited reports strong Q4 and full year FY26 results, showing significant growth and strategic execution.
